Trial reportPloS one2026
Butorphanol decreased the median effective concentration of ropivacaine in ultrasound-guided interscalene brachial plexus block.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombining butorphanol with local anesthesia can enhance the analgesic effect of local anesthesia and prolong the duration of action for nerve block anesthesia. In this study, we aimed to determine the effects of butorphanol on the median effective concentration (EC50) of ropivacaine in ultrasound-guided interscalene brachial plexus block (ISB).
methodsThis is a randomized, double-blind, up-and-down sequential allocation study. Fifty patients undergoing arthroscopic shoulder surgery under general anesthesia were randomly assigned to the ropivacaine group or the butorphanol group in a 1:1 ratio. The former received 20 mL of ropivacaine for ultrasound-guided ISB, and the latter received a mixture containing 1 mg butorphanol and 20 mL ropivacaine. The concentration of ropivacaine for the first patient was 0.4%, and the ropivacaine concentration for the next patient was determined on the basis of the response of the previous patient to 0.4% ropivacaine using Dixon's up-and-down sequential method with a ratio of 1:1.1.
resultsForty patients completed this study. The bootstrap EC50 of ropivacaine was significantly lower in the butorphanol group (0.24%, 95% CI: 0.23%-0.24%) than in the ropivacaine group (0.30%, 95% CI: 0.29%-0.31%). Compared with the ropivacaine group, the dosage of ropivacaine in the butorphanol group decreased significantly during the test. Postoperative visual analog scale scores at 8 h and 12 h were lower in the butorphanol group than in the ropivacaine group, and the need for salvage analgesia within 24 h after surgery was significantly lower in the butorphanol group.
conclusionButorphanol decreased the EC50 of ropivacaine required for ISB in patients undergoing arthroscopic shoulder surgery.
trial registrationIt was registered on October 30th, 2022 (available at http://www.chictr.org.cn, identifier: ChiCTR2200065164).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.